The healthcare market is fueling digital transformation by improving efficiency and fostering personalized care, making it an ...

With Neurocrine having finally shaken up treatment for a rare genetic hormone disease, Harbour BioMed’s antibody offshoot has ...

Cardinal Health (CAH) reported $55.26 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 3.8%. EPS of $1.93 for the same period compares to $1.82 a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cardinal Health, Inc. CAH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of $1.93, which beat the Zacks Consensus Estimate of $1.75 by 10.3%. The bottom line also improved 2 ...

Investors in Cardinal Health, Inc. (Symbol: CAH) saw new options become available today, for the March 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...

One company to watch right now is Cardinal Health (CAH). CAH is currently sporting a Zacks Rank of #2 (Buy), as well as a Value grade of A. The stock holds a P/E ratio of 14.87, while its industry ...

The rubber ball that is short-term insider sentiment has bounced yet again. Looking at the one-week sell/buy ratios from Vickers Stock Research, we'll focus initially on the Total ratio, which ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Cardinal Health, Inc. operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals ...